AxoSim partners with preclinical scientists to solve advanced problems in the drug discovery and development processes. They provide rodent and human predictive in vitro modeling via industry-leading biomimetic platforms that assist in identification of better and earlier drug candidates accurately and efficiently. For example, AxoSim's NerveSimĀ® platform facilitates prediction of both clinical neurotoxicity and efficacy in human neurodegenerative disease models earlier in the drug development pipeline. BrainSimĀ® is a high quality 3D miniature brain organoid designed to serve as a human-relevant model in preclinical drug discovery. The microBrainā¢ technology provides a physiologically-relevant human iPSC-derived screening platform for CNS drug discovery and toxicity testing.
